Fibrocell's Wrinkle Treatment: FDA Panel Supports Efficacy But Is Mixed On Safety
This article was originally published in The Pink Sheet Daily
Executive Summary
Advisory committee votes that Laviv (azfibrocel-T) is effective in improving nasolabial fold wrinkles, but that safety data are too limited to be relied upon - especially considering the inevitably widespread off-label use.
You may also be interested in...
Limited Rollout Planned For Fibrocell's Newly Approved Aesthetic Cellular Therapy
The initial indication for laViv is treatment of nasolabial fold wrinkles, but Fibrocell is eyeing additional indications for its autologous cell therapy.
Limited Rollout Planned For Fibrocell's Newly Approved Aesthetic Cellular Therapy
The initial indication for laViv is treatment of nasolabial fold wrinkles, but Fibrocell is eyeing additional indications for its autologous cell therapy.
Fibrocell's Wrinkle Drug Underlines Challenges Of Seeking Aesthetic Claims
An FDA advisory committee made very clear that the bar should be much higher for novel products proposed for aesthetic indications than for drugs to treat diseases during the Oct. 9 review of Fibrocell Science's wrinkle therapy Laviv (azfibrocel-T)